COMPANY UPDATES
16
Dec
2019
Novoheart Licenses Harvard Technology to Develop Next-Generation Human Heart-in-a-Jar

Novoheart is pleased to announce an exclusive licensing agreement with Harvard University’s Office of Technology Development. The agreement enables Novoheart to combine its state-of-the-art MyHeartTM Platform with Harvard’s pioneering tissue-engineered scale model of the heart ventricle and bioreactor technology. The valved bioreactor technology was developed in the lab of Kevin Kit Parker, PhD, who is the Tarr Family Professor of Bioengineering and Applied Physics at Harvard John A. Paulson School of Engineering and Applied Sciences, a Core Faculty member at Harvard’s Wyss Institute for Biologically Inspired Engineering and a Principal Faculty Member at the Harvard Stem Cell Institute. The resultant next-generation “human heart-in-a-jar” is expected to offer a superior human heart model for disease modeling, drug discovery and development, with unmatched biofidelity as well as significantly enhanced predictive accuracy, capacity and versatility.

Novoheart’s approach marks an important step away from using mice in traditional testing models, which have limited predictive ability for drug discovery due to key differences in genetic makeup and physiology. Novoheart’s proprietary human-specific heart models offer an innovative and powerful platform to develop new therapies and test for safety and efficacy.

 

For more detailed press release, please press here.

 

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!